Research Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Principal Investigator 
Martin Gleave

Overview

Body Locations and Systems 
Prostate Cancer
ClinicalTrials.gov# 
NCT01946204
Status 
Closed to Recruitment
Study Start/End 
Sep 3, 2013 to May 31, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Maureen Palmer, Study Coordinator
Phone 
604-875-5675
Email Address 
maureen.palmer@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer.


Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.